117 related articles for article (PubMed ID: 12753318)
1. Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation.
Fan SL; Kumar S; Cunningham J
Kidney Int; 2003 Jun; 63(6):2275-9. PubMed ID: 12753318
[TBL] [Abstract][Full Text] [Related]
2. Pamidronate therapy as prevention of bone loss following renal transplantation.
Fan SL; Almond MK; Ball E; Evans K; Cunningham J
Kidney Int; 2000 Feb; 57(2):684-90. PubMed ID: 10652047
[TBL] [Abstract][Full Text] [Related]
3. Low-dose pamidronate for treatment of early bone loss following kidney transplantation: a randomized controlled trial.
Shahidi S; Ashrafi F; Mohammadi M; Moeinzadeh F; Atapour A
Iran J Kidney Dis; 2015 Jan; 9(1):50-5. PubMed ID: 25599737
[TBL] [Abstract][Full Text] [Related]
4. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial.
Walsh SB; Altmann P; Pattison J; Wilkie M; Yaqoob MM; Dudley C; Cockwell P; Sweny P; Banks LM; Hall-Craggs M; Noonan K; Andrews C; Cunningham J
Am J Kidney Dis; 2009 May; 53(5):856-65. PubMed ID: 19393473
[TBL] [Abstract][Full Text] [Related]
5. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation.
Westeel FP; Mazouz H; Ezaitouni F; Hottelart C; Ivan C; Fardellone P; Brazier M; El Esper I; Petit J; Achard JM; Pruna A; Fournier A
Kidney Int; 2000 Oct; 58(4):1788-96. PubMed ID: 11012914
[TBL] [Abstract][Full Text] [Related]
7. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study.
Krieg MA; Seydoux C; Sandini L; Goy JJ; Berguer DG; Thiébaud D; Burckhardt P
Osteoporos Int; 2001; 12(2):112-6. PubMed ID: 11303710
[TBL] [Abstract][Full Text] [Related]
8. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant.
Torregrosa JV; Fuster D; Monegal A; Gentil MA; Bravo J; Guirado L; Muxí A; Cubero J
Osteoporos Int; 2011 Jan; 22(1):281-7. PubMed ID: 20229199
[TBL] [Abstract][Full Text] [Related]
10. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
11. Pamidronate reduces bone loss after allogeneic stem cell transplantation.
Grigg AP; Shuttleworth P; Reynolds J; Schwarer AP; Szer J; Bradstock K; Hui C; Herrmann R; Ebeling PR
J Clin Endocrinol Metab; 2006 Oct; 91(10):3835-43. PubMed ID: 16835281
[TBL] [Abstract][Full Text] [Related]
12. Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation.
Omidvar B; Ghorbani A; Shahbazian H; Beladi Mousavi SS; Shariat Nabavi SJ; Alasti M
Iran J Kidney Dis; 2011 Nov; 5(6):420-4. PubMed ID: 22057076
[TBL] [Abstract][Full Text] [Related]
13. Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study.
Marcén R; Caballero C; Pascual J; Teruel JL; Tenorio M; Ocaña J; Villafruela JJ; Burgos FJ; Fernández AM; Muriel A; Ortuño J
Transplantation; 2006 Mar; 81(6):826-31. PubMed ID: 16570003
[TBL] [Abstract][Full Text] [Related]
14. Rapid loss of vertebral mineral density after renal transplantation.
Julian BA; Laskow DA; Dubovsky J; Dubovsky EV; Curtis JJ; Quarles LD
N Engl J Med; 1991 Aug; 325(8):544-50. PubMed ID: 1857390
[TBL] [Abstract][Full Text] [Related]
15. Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction.
Lee S; Glicklich D; Coco M
Nephrol Dial Transplant; 2004 Nov; 19(11):2870-3. PubMed ID: 15466880
[TBL] [Abstract][Full Text] [Related]
16. Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up.
Tillmann FP; Schmitz M; Jäger M; Krauspe R; Rump LC
Int Urol Nephrol; 2016 Feb; 48(2):279-86. PubMed ID: 26498632
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic bone marrow transplantation is associated with a preferential femoral neck bone loss.
Buchs N; Helg C; Collao C; Chapuis B; Slosman D; Bonjour JP; Rizzoli R
Osteoporos Int; 2001; 12(10):880-6. PubMed ID: 11716193
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density after kidney transplantation. A cross-sectional study in 190 graft recipients up to 20 years after transplantation.
Grotz WH; Mundinger FA; Gugel B; Exner VM; Kirste G; Schollmeyer PJ
Transplantation; 1995 Apr; 59(7):982-6. PubMed ID: 7709459
[TBL] [Abstract][Full Text] [Related]
19. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate.
Coco M; Glicklich D; Faugere MC; Burris L; Bognar I; Durkin P; Tellis V; Greenstein S; Schechner R; Figueroa K; McDonough P; Wang G; Malluche H
J Am Soc Nephrol; 2003 Oct; 14(10):2669-76. PubMed ID: 14514747
[TBL] [Abstract][Full Text] [Related]
20. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation.
Ninkovic M; Love S; Tom BD; Bearcroft PW; Alexander GJ; Compston JE
J Hepatol; 2002 Jul; 37(1):93-100. PubMed ID: 12076867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
